Literature DB >> 10447777

Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.

A Meager1, M Wadhwa, C Bird, P Dilger, R Thorpe, J Newsom-Davis, N Willcox.   

Abstract

There is increasing evidence that spontaneous anticytokine autoantibodies are associated with chronic infections and autoimmune diseases. We report the sporadic occurrence in autoimmune diseases of such autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine involved in inflammation and the regulation of proliferation, differentiation and function of granulocytic and monocytic cell lineages. In 41 of 425 patients tested, we found low to moderate levels of autoantibodies binding to GM-CSF in serum or plasma. These were most prevalent in patients with myasthenia gravis (MG). However, neutralizing autoantibodies against GM-CSF were very rare, being found in only three patients. Two had autoimmune MG, one with thymoma (Patient A) and the other (Patient B) with 'seronegative' MG, i.e. without the antiacetylcholine receptor autoantibodies characteristic of most MG patients, and a third (Patient D) had multiple sclerosis. Only very limited amounts of Patient A and Patient D serum/plasma were available for analysis and therefore further studies were carried out on the more plentiful samples from Patient B. The anti-GM-CSF autoantibodies of Patient B were predominantly polyclonal immunoglobulin G and strongly neutralized recombinant human (rh) GM-CSF derived from different expression systems. They had similar immunological and immunochemical characteristics to anti-GM-CSF antibodies that developed in immunocompetent colorectal carcinoma patients following (rh)GM-CSF therapy. In serial samples from Patient B, the anti-GM-CSF autoantibodies were undetectable from diagnosis at age 8 years until at least age 13, but then developed spontaneously during (temporary) withdrawal of immunosuppressive treatment. Their neutralizing activity has persisted since their first detection at age 15 years 1 month, and was at its highest level recently at age 17 years 7 months. There was no obvious association with other autoimmune phenomena, nor were any haematological deficiencies overtly manifested, suggesting that any loss of GM-CSF function may have been compensated for by other cytokines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447777      PMCID: PMC2326850          DOI: 10.1046/j.1365-2567.1999.00806.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Acquired cyclic amegakaryocytic thrombocytopenia associated with an immunoglobulin blocking the action of granulocyte-macrophage colony-stimulating factor.

Authors:  R Hoffman; R A Briddell; K van Besien; E F Srour; T Guscar; N W Hudson; A Ganser
Journal:  N Engl J Med       Date:  1989-07-13       Impact factor: 91.245

2.  Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis.

Authors:  H Takemura; H Suzuki; K Yoshizaki; A Ogata; T Yuhara; T Akama; K Yamane; H Kashiwagi
Journal:  Arthritis Rheum       Date:  1992-08

3.  Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum.

Authors:  I Sylvester; T Yoshimura; M Sticherling; J M Schröder; M Ceska; P Peichl; E J Leonard
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma: case report and literature review.

Authors:  P W Mathieson; J H O'Neill; S T Durrant; S J Henderson; P J Green; J Newsom-Davis
Journal:  Q J Med       Date:  1990-01

5.  Natural antibodies to IFN-gamma in man and their increase during viral infection.

Authors:  A Caruso; C Bonfanti; D Colombrita; M De Francesco; C De Rango; I Foresti; F Gargiulo; R Gonzales; G Gribaudo; S Landolfo
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

6.  Anti-interleukin-6 antibodies in normal human serum.

Authors:  M B Hansen; M Svenson; M Diamant; K Bendtzen
Journal:  Scand J Immunol       Date:  1991-06       Impact factor: 3.487

7.  Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera.

Authors:  M Svenson; M Bagge Hansen; K Bendtzen
Journal:  Scand J Immunol       Date:  1990-12       Impact factor: 3.487

8.  Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin.

Authors:  T Kitamura; T Tange; T Terasawa; S Chiba; T Kuwaki; K Miyagawa; Y F Piao; K Miyazono; A Urabe; F Takaku
Journal:  J Cell Physiol       Date:  1989-08       Impact factor: 6.384

9.  Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity.

Authors:  S Mossman; A Vincent; J Newsom-Davis
Journal:  Lancet       Date:  1986-01-18       Impact factor: 79.321

Review 10.  Interferon-alpha antibodies in autoimmune diseases.

Authors:  O Prümmer; C Seyfarth; W A Scherbaum; N Drees; F Porzsolt
Journal:  J Interferon Res       Date:  1989-09
View more
  13 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

3.  Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).

Authors:  Lisa H Butterfield; Fengmin Zhao; Sandra Lee; Ahmad A Tarhini; Kim A Margolin; Richard L White; Michael B Atkins; Gary I Cohen; Theresa L Whiteside; John M Kirkwood; David H Lawson
Journal:  Clin Cancer Res       Date:  2017-05-23       Impact factor: 12.531

4.  GM-CSF: a role in immune and inflammatory reactions in the intestine.

Authors:  Laia Egea; Yoshihiro Hirata; Martin F Kagnoff
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-12       Impact factor: 3.869

5.  Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

Authors:  Kanji Uchida; Koh Nakata; Takuji Suzuki; Maurizio Luisetti; Masato Watanabe; Diana E Koch; Carrie A Stevens; David C Beck; Lee A Denson; Brenna C Carey; Naoto Keicho; Jeffrey P Krischer; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

6.  Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.

Authors:  B Hellmich; A Ciaglo; H Schatz; G Coakley
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

7.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

8.  Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders?

Authors:  D Melis; F Balivo; R Della Casa; A Romano; R Taurisano; B Capaldo; G Riccardi; M R Monsurrò; G Parenti; G Andria
Journal:  J Inherit Metab Dis       Date:  2008-04-21       Impact factor: 4.982

9.  Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis.

Authors:  A Meager; M Wadhwa; P Dilger; C Bird; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

Review 10.  Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

Authors:  Christoph Hoeller; Olivier Michielin; Paolo A Ascierto; Zsolt Szabo; Christian U Blank
Journal:  Cancer Immunol Immunother       Date:  2016-07-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.